The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
- Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
April 8, 2022
- Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
March 16, 2022
- Drug Makers in Japan Increasingly Tested for Product Prowess, Rather than Marketing Ability
February 25, 2022
- Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
February 16, 2022
- JPMA Chief’s Comments to Endorse Coverage Review Send Ripples through Industry
February 3, 2022
- Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
January 17, 2022
- Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
- Public-Private Collaboration Needed to Refine SaMD Regulatory System
November 26, 2021
- MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
November 16, 2021
- SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
October 26, 2021
- LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
October 19, 2021
- Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
- Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
- 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
- Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
June 22, 2021
- Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
June 1, 2021
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…